Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfredo Berruti

Showing results (1-10 of 379) with videos related to

Pageof 38
Sort By:
Minerva Urology and Nephrology|March 25, 2021
Could a comprehensive urinary endogenous steroidal profile improve the accuracy of prostate-specific antigen screening?Alfredo Berruti, Salvatore Grisanti
Current Opinion in Endocrinology, Diabetes, and Obesity|April 29, 2008
Adjunctive treatment of adrenocortical carcinomaMassimo Terzolo, Alfredo Berruti
Hormones & Cancer|January 6, 2016
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical CarcinomaAna O Hoff, Alfredo Berruti
Handbook of Experimental Pharmacology|March 30, 2017
Resistance to Hormonal Therapy in Prostate CancerAlfredo Berruti, Alberto Dalla Volta
The New England Journal of Medicine|March 30, 2018
Osimertinib in EGFR Mutation–Positive Advanced NSCLCElisa Roca, Vito Amoroso, Alfredo Berruti
Endocrine|July 22, 2022
Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1-2, 2021Alfredo Berruti, Massimo Terzolo, Sebastiano Filetti
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2013
Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?Laura Deiana, Melanie Claps, Alfredo Berruti
The New England Journal of Medicine|February 11, 2026
Belzutifan for Advanced Pheochromocytoma or Paraganglioma. ReplyCamilo Jimenez, Mikkel Andreassen, Alfredo Berruti
The New England Journal of Medicine|April 25, 2008
Major depressive disorderAndrea Saini, Mara Ardine, Alfredo Berruti
Cancers|October 27, 2022
Endocrine and Neuroendocrine Tumors: A Special IssueAlfredo Berruti, Vito Amoroso, Nicola Fazio
Pageof 38

Showing results (1-10 of 379) with videos related to

Sort By:
Pageof 38
Minerva Urology and Nephrology|March 25, 2021
Could a comprehensive urinary endogenous steroidal profile improve the accuracy of prostate-specific antigen screening?Alfredo Berruti, Salvatore Grisanti
Current Opinion in Endocrinology, Diabetes, and Obesity|April 29, 2008
Adjunctive treatment of adrenocortical carcinomaMassimo Terzolo, Alfredo Berruti
Hormones & Cancer|January 6, 2016
5th International ACC Symposium: Future and Current Therapeutic Trials in Adrenocortical CarcinomaAna O Hoff, Alfredo Berruti
Handbook of Experimental Pharmacology|March 30, 2017
Resistance to Hormonal Therapy in Prostate CancerAlfredo Berruti, Alberto Dalla Volta
The New England Journal of Medicine|March 30, 2018
Osimertinib in EGFR Mutation–Positive Advanced NSCLCElisa Roca, Vito Amoroso, Alfredo Berruti
Endocrine|July 22, 2022
Eighth International Adrenal Cancer Symposium Brescia, Italy, September 30 to October 1-2, 2021Alfredo Berruti, Massimo Terzolo, Sebastiano Filetti
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|July 17, 2013
Why denosumab obtains a survival benefit over zoledronic acid in bone metastatic lung cancer patients?Laura Deiana, Melanie Claps, Alfredo Berruti
The New England Journal of Medicine|February 11, 2026
Belzutifan for Advanced Pheochromocytoma or Paraganglioma. ReplyCamilo Jimenez, Mikkel Andreassen, Alfredo Berruti
The New England Journal of Medicine|April 25, 2008
Major depressive disorderAndrea Saini, Mara Ardine, Alfredo Berruti
Cancers|October 27, 2022
Endocrine and Neuroendocrine Tumors: A Special IssueAlfredo Berruti, Vito Amoroso, Nicola Fazio
Pageof 38